FAST STATS 2.8 MILLION+
antibiotic-resistant infections occur each year in the United States, resulting in the deaths of more than 35,000 Americans, according to the CDC’s updated estimates in 2019.
$4.8 BILLION+
in medical costs were caused by a subset of resistant infections in 2017, estimated the CDC.
38%
decline occurred between 2015 and 2018 in medically important antibiotics sold for use in food-producing animals, reported the FDA in 2019.
18%
decrease occurred in the overall number of U.S. deaths from antibiotic-resistant infections from 2012 to 2017.
30%
decrease occurred in the number of U.S. deaths from resistant infections in hospitals as a result of efforts to prevent infections and control their spread.
20%
decrease in healthcare-associated antibiotic- resistant infections by 2025 is an objective for the CDC.
10%
decrease in community-acquired antibiotic- resistant infections by 2025 is an objective for the CDC.
10
new antibiotic resistance-related diagnostics projects across the U.S. Government by 2021, through funding or scientifi c or technical support, are an objective for ASPR/BARDA, CDC, FDA, NIH, ARS, and DoD.
100 new projects (e.g., grants, contracts, CARB-X
awards) awards aimed at therapeutic discovery or development by 2024 are an objective for ASPR/BARDA.
Citation: NATIONAL ACTION PLAN FOR COMBATING ANTIBIOTIC- RESISTANT BACTERIA 2020-2025, October 2020, From the Federal Task Force on Combating Antibiotic-Resistant Bacteria, h� ps://www.
hhs.gov/sites/default/fi les/carb-na� onal-ac� on-plan-2020-2025.pdf
Photo by freestocks on Unsplash 6
NEWSWIRE
SMI announces Jane Pleasants as new Executive Director I, a non-profi t, member-driven com- munity of healthcare supply chain thought- leaders has announced that effective ebruary , , om ughes will begin serving as I ecutive irector, meritus and ane leasants will assume the leader- ship role of I ecutive irector. leasants will start her new position on ebruary , following her retirement after many years as the vice president of supply chain at uke ealth. er supply chain career has spanned more than 3 decades and in addition to her many accom- plishments at uke, she has led supply chain teams at both anderbilt Univer- sity and University of ochester. s an I founder, long-serving member on the oard of irectors, oard hair- lect and cur- rent hairman of the oard she is a highly visible member of the
Jane Pleasants Tom Hughes
I community and also was inducted into the ellwether eague all of ame for ealthcare upply hain eadershipin . he brings etensive knowledge, eperience, and purpose to lead the net chapter of I. ughes has held the position of eecu-
tive director of I for years after a long-standing career in healthcare. Under his leadership, vision, and dedication, I has grown to more than 3 member orga- nizations, which represent the nations top providers, suppliers, manufacturers, dis- tributors and innovators, like ohnson ohnson, 3, bbott, aiser ermanente, scension and mazon. e began on the front lines of hospital administration before founding oncepts in ealthcare, a healthcare supply chain consultancy, and after the sale of this company to , he ultimately became the vice president of ealthcare onsulting ervices. e is recognized for pioneering new approaches for provider-supplier relationships and has been a respected mentor, innovator, advisor, and leader to many in the health- care supply chain industry. ughes is the recipient of s eorge . ossett eadership ward and was inducted into the ellwether eague all of ame for ealthcare upply hain eadership in .
November 2020 • HEALTHCARE PURCHASING NEWS •
hpnonline.com
teve undersen, ice resident and eneral anager of , a founding mem- ber of I and hair-lect said, Ive had the pleasure of knowing ane and om for many years. oth are visionaries who have had a profound impact improving supply chain processes for clinicians and patients. oms countless contributions will be felt throughout the healthcare supply chain industry for years to come. anes willing- ness to listen, connect and contribute make her uniuely ualifi ed to be the net leader of I. It has been an honor to know them both as colleagues and dear friends. I am ecited for this net new chapter for ane, om and I.
National action plan for combating antibiotic-resistant bacteria updated for 2020-2025 he ational ction lan for ombating ntibiotic-esistant acteria , - , presents coordinated, strategic actions that the United tates overnment will take in the net fi ve years to improve the health and wellbeing of all mericans by changing the course of antibiotic resistance. his plan is based on the U.. overn- ments ational trategy for , and builds on the fi rst ational ction lan released in by epanding evidence- based activities that have already been shown to reduce antibiotic resistance, such as optimizing the use of antibiotics in human and animal health settings. his plan continues to prioritize infection prevention and control to slow the spread of resistant infections and reduce the need for antibiotic use. o ensure that patients receive the right antibiotic care, the lan supports innovative approaches to devel- oping and deploying diagnostic tests and treatment strategies. ne ealth approach, which recog-
nizes the relationships between the health of humans, animals, plants, and the envi- ronment, is integrated throughout the lan, with an epanded effort to understand anti- biotic resistance in the environment. he lan also focuses on collecting and using data to better understand where resistance is occurring, support the development of new diagnostics and treatment options, and advance international coordination. o address the growing threat of anti-
biotic resistance, the U.. overnment released the ational trategy for in eptember , which outlined five inter-related goals to guide ederal action. t the same time, ecutive rder 3 established the ederal ask orce for to identify actions to implement the ational trategy. In arch , the ask orce released the fi rst ational ction
Page 8
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66
